Literature DB >> 8017856

Ifosfamide metabolism and pharmacokinetics (review).

G P Kaijser1, J H Beijnen, A Bult, W J Underberg.   

Abstract

In this article the studies on the pharmacokinetics and metabolism of ifosfamide have been summarised. Ifosfamide is a pro-drug and requires metabolic activation to exert cytotoxic activity. The various metabolites determined after oral or intravenous administration of ifosfamide show a large inter- and intrapatient variability. Oral and intravenous fractionated treatment with ifosfamide exhibits a time-dependent increase in ifosfamide metabolic clearance which is explained by a mechanism of auto-induction of the hepatic oxygenase system. The pharmacokinetic parameters of ifosfamide do not correlate with age, sex and weight. Oral ifosfamide, at a dose higher than 1 g/m2, induces neurotoxicity in a high percentage of patients. In these cases the pharmacokinetics of ifosfamide were not aberrant. This implies that ifosfamide metabolites rather than the parent drug are likely to be responsible for the neurotoxicity. The development of more selective and sensitive analytical methodologies are necessary in order to go in more insight into the disposition of the active ifosfamide metabolites, including their clinical effects. This may lead to a further optimisation of the therapeutic use of ifosfamide.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8017856

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  12 in total

1.  Human metabolites and transformation products of cyclophosphamide and ifosfamide: analysis, occurrence and formation during abiotic treatments.

Authors:  Marjeta Česen; Tina Kosjek; Francesco Busetti; Boris Kompare; Ester Heath
Journal:  Environ Sci Pollut Res Int       Date:  2016-02-27       Impact factor: 4.223

Review 2.  Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites.

Authors:  T Kerbusch; J de Kraker; H J Keizer; J W van Putten; H J Groen; R L Jansen; J H Schellens; J H Beijnen
Journal:  Clin Pharmacokinet       Date:  2001-01       Impact factor: 6.447

Review 3.  Metabolism and pharmacokinetics of oxazaphosphorines.

Authors:  A V Boddy; S M Yule
Journal:  Clin Pharmacokinet       Date:  2000-04       Impact factor: 6.447

4.  Population pharmacokinetics of ifosfamide and its dechloroethylated and hydroxylated metabolites in children with malignant disease: a sparse sampling approach.

Authors:  T Kerbusch; J de Kraker; R A Mathĵt; J H Beijnen
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

5.  New insights into the pharmacokinetics and metabolism of (R,S)-ifosfamide in cancer patients using a population pharmacokinetic-metabolism model.

Authors:  M P Di Marco; I W Wainer; C L Granvil; G Batist; M P Ducharme
Journal:  Pharm Res       Date:  2000-06       Impact factor: 4.200

6.  Central Nervous System Involvement of Rhabdomyosarcoma: A Single Institution Experience.

Authors:  Daniel C Moreira; Margaret E Macy; Carrye R Cost; Brian S Greffe; Timothy P Garrington
Journal:  J Pediatr Hematol Oncol       Date:  2019-03       Impact factor: 1.289

7.  In vivo mesna and amifostine do not prevent chloroacetaldehyde nephrotoxicity in vitro.

Authors:  Zeinab Yaseen; Christian Michoudet; Gabriel Baverel; Laurence Dubourg
Journal:  Pediatr Nephrol       Date:  2008-01-18       Impact factor: 3.714

8.  Ifosfamide-related encephalopathy in elderly patients : report of five cases and review of the literature.

Authors:  Antonella Brunello; Umberto Basso; Elena Rossi; Micaela Stefani; Cristina Ghiotto; Dario Marino; Gino Crivellari; Silvio Monfardini
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

Review 9.  Practical treatment guide for dose individualisation in cancer chemotherapy.

Authors:  P Canal; E Chatelut; S Guichard
Journal:  Drugs       Date:  1998-12       Impact factor: 9.546

10.  The pharmacokinetics and metabolism of ifosfamide during bolus and infusional administration: a randomized cross-over study.

Authors:  J M Singer; J M Hartley; C Brennan; P W Nicholson; R L Souhami
Journal:  Br J Cancer       Date:  1998-03       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.